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Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are often linked to
respiratory infections. However, it is unknown if COPD patients who experience frequent exacerbations have
impaired humoral immunity. The aim of this study was to determine if antibodies specific for common respiratory
pathogens are associated with AECOPD.
Methods: Plasma was obtained from COPD patients when clinically stable. AECOPD requiring hospitalisation were
recorded. IgG1 antibodies to H. Influenzae outer membrane protein 6 (P6), pneumococcal surface protein C (PspC)
and the VP1 viral capsid protein of rhinovirus were measured.
Results: COPD patients who had an AECOPD (n = 32) had significantly lower anti-VP1 IgG1 antibody levels when
stable compared to COPD patients who did not have an AECOPD (n = 28, p = 0.024). Furthermore, the number of
hospitalisations was inversely proportional to anti-VP1 antibody levels (r =−0.331, p = 0.011). In contrast, antibodies
specific for P6 and PspC were present at similar concentrations between groups. Plasma IL-21, a cytokine important
for B-cell development and antibody synthesis, was also lower in COPD patients who had an AECOPD, than in
stable COPD patients (p = 0.046).
Conclusion: Deficient humoral immunity specific for rhinoviruses is associated with AECOPD requiring
hospitalisation, and may partly explain why some COPD patients have an increased exacerbation risk following
respiratory viral infections.Background
Acute exacerbations of chronic obstructive pulmonary
disease (COPD) are responsible for much of the morbid-
ity, mortality and health care costs associated with
COPD. Exacerbations are associated with poor clinical
outcomes including accelerated decline of lung function
[1], reduced quality of life [2] and an increased risk of
death [3]. Despite the clinical importance of exacerba-
tions, it is not entirely clear why some COPD patients* Correspondence: j.upham@uq.edu.au
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reproduction in any medium, provided the orexperience frequent exacerbations, while others remain
relatively stable. Though exacerbations tend to become
more frequent in those with poor lung function, it has
recently been shown that the single best predictor of
exacerbations is a history of previous exacerbations [4].
Susceptibility to exacerbations is also associated with
bacterial colonisation of the airways during periods of
clinical stability [5], with the presence of gastro-
oesophageal reflux and with an elevated white blood cell
count [4].
Many COPD exacerbations are triggered by respiratory
infections with bacteria such as Haemophilus influenzae
and Streptococcus pneumoniae frequently cultured from
sputum [5]. In addition, the development of sensitiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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appreciation of the importance of respiratory viruses as
triggers of exacerbations; human rhinoviruses are the
most common viruses identified in this situation [6,7].
Some patients with COPD appear unusually suscep-
tible to microbial pathogens, though the mechanisms
mediating this susceptibility are not well understood.
Hence there is a need for a more detailed analysis of
anti-microbial immunity in COPD, and the extent to
which this is associated with exacerbations. We hypothe-
sized that those COPD patients with a relative baseline
deficiency in circulating antibodies specific for common
viral and bacterial pathogens would be at greater risk for
COPD exacerbations.
Therefore, the aim of this study was to measure the
concentrations of IgG1 antibodies specific for conserved
antigens within human rhinoviruses, H. influenzae and
S. pneumoniae in a group of COPD patients studied at a
time of clinical stability, and to relate this to the presence
or absence of exacerbations requiring hospitalisation
over a twelve month period. This is pertinent as COPD
patients who are hospitalised with an exacerbation have a
higher mortality rate over subsequent years compared to
COPD patients not hospitalised [8]. The study focused
on antibodies specific for the following immunogenic
proteins: (i) outer membrane protein 6 (P6) of H. influen-
zae, because reduced concentrations of anti-P6 IgG1
antibody are a risk factor for asthma exacerbations in
children [9], (ii) pneumococcal surface protein C (PspC),
because anti-PspC antibodies can mediate host protec-
tion against S. pneumoniae [10], and (iii) a type A con-
served rhinovirus outer capsid protein (VP1) as type
A rhinoviruses are the most common, and anti-VP1
antibodies exhibit cross-neutralizing activity across dif-
ferent rhinovirus strains in vivo [11]. Furthermore, be-
cause IL-21 is a cytokine that is important for B-cell
development and antibody synthesis [12], circulating
IL-21 was also measured.
Methods
Patient recruitment
We recruited sixty COPD patients as previously
described [13], all of whom met ERS/ATS criteria for a
clinical definition of COPD. Patients with other lung dis-
eases or malignancy were not enrolled. The severity of
COPD was graded as per the global initiative for chronic
obstructive lung disease (GOLD) criteria: all patients
had GOLD stage 2, 3 or 4 disease [14]. Exacerbations
were defined by standard criteria as two out of three of
increased sputum production, increased dyspnoea or
change in sputum colour [14]. Full details of the cohort
have been described previously [13]. This study was
approved by the Human Research Ethics Committee,
Princess Alexandra Hospital, Australia and patientsprovided informed written consent prior to their enrol-
ment in the study.Blood sampling
Blood samples were collected from patients at a time
when they had been clinically stable for at least 6 weeks.
Importantly, blood sampling was not performed within
6 weeks of finishing a course of oral steroids. Plasma
was stored at −20°C for later batch analysis.Antigen preparation
The P6 outer membrane protein of H. influenzae from
the Eagen isolate and VP1 from human rhinovirus 1B
(rhinovirus species A) were produced as fusion polypep-
tides with N-terminal hexa-histidine tags in pQE-80 L
(Novagen, Madison, USA). PspC was derived from the
pneumococcal D39 strain (aa 1–445) and cloned with
a C-terminal six-histidine tag in pET20b (Novagen).
The pQE-80 L and pET20b-based constructs were
expressed in BL21 Star (DE3) pLysS (Novagen) using
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG), in
the presence of 100 μg/ml ampicillin and 34 μg/ml chlor-
amphenicol (Invitrogen Corp., Carlsbad, USA). The
expressed recombinant proteins were purified under
non-denaturing conditions using Ni2+-nitrilotriacetic
acid (Ni-NTA) agarose chromatography (Qiagen GmbH,
Germany), according to the manufacturer’s protocols.
Fractions containing the relevant protein were pooled
and further purified using anion/cation and size exclu-
sion chromatography. The purities of all the proteins
were checked on a 12.5% sodium dodecyl sulfate-
polyacrylamide gel and the concentrations determined
using the optical density at 280 nm (OD280) measure-
ments and extinction coefficients.Measurement of specific antibodies
Anti-P6 IgG1 antibodies, anti-PspC IgG1 antibodies
and anti-VP1 IgG1 antibodies were measured using
dissociated-enhanced immunofluoresence assay (DEL-
FIA™) as described previously [15]. The limit of detection
was 100 ng/ml. Patients who had values below the limit
of detection were assigned a value of half the lower limit
of detection [16].Measurement of CRP and IL-21 levels
CRP was measured as an index of systemic inflammation
by the hospital pathology service using commercial
auto-analysers. IL-21 was measured in plasma using a
commercial ELISA kit (eBiosciences, San Diego, CA)
according to the manufacturer’s instructions. The lower
detection limit of this assay was 15.5 pg/ml.
Table 1 Subject Characteristics
Stable COPD Patients n = 28 Exacerbation-prone COPD Patients n = 32 p value
Age, 69.8 69.6 0.917
median (IQ range) (62.9 – 73.4) (62.8 – 74.2)
Male, n (%) 15 (54) 21 (66) 0.431
Smoker current, n (%) 8 (26) 9 (28) 1.00
Smoking pack years, median (IQ range) 53 (37–72) 45 (35 – 72) 0.721
FEV1 % predicted, median (IQ range) 46 (35 – 60) 31 (21 – 45) 0.001
Inhaled steroids, n (%) 19 (68) 26 (81) 0.251
Number of hospitalisations, median (IQ range) 0 2 (1 – 4.5)
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Data was assessed using Stata v11 (StataCorp, USA) with
p< 0.05 considered statistically significant. As the data
was not normally distributed, group differences were
assessed using Kruskal-Wallis test, Mann–Whitney U test
for unpaired responses or Fisher’s Exact Test, as appropri-
ate. Correlations between variables were assessed using
Spearman’s rank test. Simple and multivariate linear
regressions were performed with exacerbation history as
the dependent variable. Variables where the residuals were
not normally distributed were natural log transformed.
Simple linear regression analysis was initially used to
evaluate the relationship between variables and exacerba-
tion history and those variables in which p< 0.1 were then
subjected to multiple linear regression analysis. The final
model was obtained by backwards selection, retaining pre-
dictors that were statistically significant at α= 0.05.
Results
Subject demographics
The demographic characteristics of the patients are shown
in Table 1. The patients were middle aged to elderlyFigure 1 Anti-rhinovirus IgG1 antibodies in COPD. (A) IgG1 antibody lev
prone COPD patients with the medians indicated. The lower limit of detec
Mann–Whitney test with significant differences indicated. (B) The relationsh
specific to rhinovirus (VP1) is shown with the regression line. The correlatio(median age 69 years). All had smoked, though less than
30% were currently smoking. Thirty-two COPD patients
had at least one exacerbation requiring hospitalisation
during the 12 month study period (median = 2; inter-
quartile range 1 – 4.5) and are hereafter referred to as
‘exacerbation-prone COPD’. The majority of exacerba-
tions occurred in winter and spring, times when mul-
tiple respiratory pathogens are circulating in the
community. Twenty-eight COPD patients were free of
exacerbations requiring hospitalisation during this
period, and are referred to as ‘stable COPD’. Importantly,
the exacerbation-prone and stable COPD patients did
not differ significantly in age, sex, pack years of smoking
or inhaled steroid usage, though the exacerbation-prone
COPD patients had more severe airflow limitation than
the stable COPD patients (p = 0.001).
Rhinovirus-specific antibody concentrations
IgG1 antibodies specific for the VP1 rhinovirus capsid
antigen could be detected in the plasma of almost all the
study participants (Figure 1A). Exacerbation-prone
COPD patients had significantly lower concentrations ofels specific to rhinovirus (VP1) are plotted for stable and exacerbation-
tion is highlighted with a dotted line. Significance was assessed by
ip between the number of hospitalisations and IgG1 antibody levels
n was assessed using the Spearman rank test.
Figure 2 IgG1 antibodies to common bacterial respiratory pathogens in COPD IgG1 antibody levels to (A) H. influenzae (P6) and (B)
pneumococcal surface antigen (PspC) are plotted for stable and exacerbation-prone COPD patients, with the medians indicated. The
lower limit of detection is highlighted with a dotted line.
Table 2 Association between anti-VP1 antibodies and
clinical factors
Correlation with anti-VP1 antibodies
Age (years) r =−0.281, p = 0.030
FEV1 % predicted r = 0.224, p = 0.085
CRP (mg/L) r =−0.159, p = 0.239
Smoking history (pack years) r = 0.171, p = 0.196
Comparison of anti-VP1 antibodies
between groups
p value
Sex (male vs female) p = 0.774
Season of blood sampling
(summer, winter, spring, autumn)
p = 0.351
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(p = 0.024). When the anti-VP1 IgG1 antibody concentra-
tions were divided into tertiles, those in the lowest tertile
had the highest risk of hospitalisation over 12 months
(median = 2 admissions), while those in the middle tertile
(median = 0 admissions) and upper tertiles (median = 0
admissions) had significantly fewer hospitalisations
(lower tertile vs middle tertile, p = 0.02; lower tertile vs
upper tertile, p = 0.02; middle tertile vs upper tertile,
p = 0.8). Similarly, the number of hospitalisations was in-
versely proportional to the anti-VP1 IgG1 antibody con-
centration (r =−0.331, p = 0.011; Figure 1b). It is
noteworthy that the only patient to have no detectable
anti-VP1 IgG1 antibodies had the highest number of
hospital admissions (n = 7).
Haemophilus- and pneumococcus-specific antibody
concentrations
IgG1 antibodies specific for the H. influenzae antigen P6
could be detected in plasma in 53% (15/28) of stable and
47% (15/32) of exacerbation-prone individuals with
COPD (Figure 2). PspC-specific IgG1 antibodies could
be detected in 68% (19/28) of subjects with stable COPD
and 56% (18/32) of COPD subjects prone to exacerba-
tion. Plasma concentrations of P6 and PspC antibodies
tended to be slightly lower in exacerbation-prone COPD
patients than in stable COPD patients, but these differ-
ences were not statistically significant (Figure 2).
Associations between anti-VP1 IgG1 and clinical variables
There was a modest inverse relationship between anti-
VP1 IgG1 and age (r =−0.281, p = 0.030), such that older
individuals generally had lower anti-VP1 IgG1 than
younger individuals (Table 2). However it should be
emphasised that there was no difference in age between
the exacerbation-prone and stable COPD patients. Anti-VP1 IgG1 antibody concentrations did not vary signifi-
cantly in relation to FEV1, sex, current or previous
smoking history, season of blood sampling or CRP
(Table 2).
In order to understand factors that predict exacerba-
tion history, univariate and multivariate linear modelling
was performed and is summarised in Table 3. Both low
lung function and low anti-VP1 IgG1 levels were inde-
pendent predictors of more frequent exacerbations.
Circulating IL-21 is significantly lower in exacerbation-
prone COPD patients
In order to assess potential mechanisms responsible for
the reduced rhinovirus-specific antibody levels observed
in exacerbation-prone COPD patients, we measured
IL-21 in plasma. Exacerbation-prone COPD patients had
significantly lower IL-21 than stable COPD patients
(p = 0.046, Figure 3A). Furthermore, plasma IL-21 levels
were inversely proportional to the number of AECOPD
requiring hospital admission (r =−0.279, p = 0.032,
Figure 3B). While IL-21 was negatively correlated to
smoking pack year history (r =−0.286, p = 0.030), IL-21
Table 3 Factors associated with exacerbation frequency
Univariate analysis β p 95% CI for β
*FEV1 % predicted −1.664 0.002 −2.700 – −0.628
*anti-VP1 IgG1 levels −0.440 0.001 −0.700 – −0.179
Use of inhaled steroids 0.978 0.092 −0.164 – 2.119
Multivariate analysis β p 95% CI for β
*FEV1 % predicted −1.388 0.007 −2.378 – −0.398
*anti-VP1 IgG1 levels −0.374 0.004 −0.625 – −0.123
* variables were natural log-transformed.
Only variables with p< 0.01 are shown in the table. r2 of the multivariate
linear regression = 0.266.
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current smoking status (data not shown).
Discussion
The key finding to emerge from this study was that
exacerbation-prone COPD patients have significantly
lower circulating anti-VP1 IgG1 and significantly lower
plasma IL-21 than stable COPD patients. Interestingly
exacerbation-prone and stable COPD patients had simi-
lar concentrations of IgG1 antibodies specific for the two
bacterial antigens examined in this study, so there was
no evidence of a generalised deficiency of humoral im-
munity to other common respiratory pathogens.
Previous studies in healthy individuals have shown that
circulating rhinovirus-specific antibodies prior to virus
exposure are related to subsequent symptom severity
and duration during an infection [17], highlighting the
importance of humoral immunity against rhinoviruses.
Moreover, it has recently been shown in an animal model
that anti-VP1 antibodies exhibit cross-neutralizing ac-
tivity across different rhinovirus strains [11]. We there-
fore propose that the lower concentrations of anti-VP1
IgG1 observed in exacerbation-prone COPD patientsFigure 3 Circulating IL-21 is lower in exacerbation-prone COPD patien
exacerbation-prone COPD patients with the median indicated and (B)
are indicated.places them at greater risk of infections due to a var-
iety of rhinovirus strains, and that this may contribute
to increased risk for COPD exacerbations. There is
strong evidence that COPD exacerbations in which a
virus is identified are more likely to result in hospital
admission [6], and that rhinoviruses are the most fre-
quent virus detected in this situation [7]. Rhinovirus
infections may also induce more symptoms and a
greater inflammatory response in COPD patients than
in healthy individuals [18].
We considered whether other variables might have
confounded our results, but found no evidence that sex,
smoking history or season was related to anti-VP1 IgG1
antibody concentrations. While increasing age was asso-
ciated with lower anti-VP1 IgG1, it should be emphasised
that the exacerbation-prone and stable COPD patients
were of similar age and the significant difference in VP1
antibodies levels between the two groups remained when
corrected for age. Though exacerbation-prone COPD
patients had more severe airflow obstruction than the
stable COPD patients, the association between lower
anti-VP1 IgG1 antibody concentrations and COPD
exacerbations appeared to be independent of FEV1
(Table 2 and 3).
In seeking to understand the mechanisms that might
lead to lower concentrations of anti-VP1 IgG1 antibody
we also measured circulating IL-21. This cytokine is
thought to be important for B-cell development and anti-
body synthesis [12]. Exacerbation-prone COPD patients
certainly had significantly lower plasma IL-21 than stable
COPD patients, but there was no statistically significant
association between IL-21 and anti-VP1 IgG1 antibody
concentrations in our patients. This might be explained
by a lack of statistical power, or alternatively, deficient
synthesis of IL-21 might be linked to COPD exacerba-
tions via other mechanisms. There is evidence that IL-21ts Plasma IL-21 levels are plotted for (A) stable and
against the number of hospital admissions. Significant differences
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studies will need to assess the relationship between IL-21,
CD8 T cell function and COPD exacerbations.
We can speculate that inflammatory cytokines and
oxidative stress might interfere with antibody synthesis,
and this is an issue that warrants further study. Systemic
inflammation (as measured by CRP) was not related to
anti-VP1 IgG1 antibody concentrations. Recent reports
indicates that airway epithelial cells from patients with
COPD are more susceptible to rhinovirus infection
in vitro [20], and that experimental rhinovirus infection
induces less innate interferon-α/β/λ synthesis in lung lav-
age cells from subjects with COPD, as compared to
healthy subjects [18]. However, little attention to date has
been given to adaptive immunity to rhinoviruses and how
this might impact on the risk of COPD exacerbations.
One limitation of our study is that we do not have in-
formation on whether the exacerbation-prone COPD
patients might have isolated themselves from contact
with children, and therefore had less exposure to rhino-
viruses. While social isolation might theoretically explain
lower anti-VP1 IgG1, one would expect that isolation
would also lead to lower exposure to H. influenzae and
S.pneumoniae and thus lower detection of anti-PspC and
anti-P6 IgG1 antibodies, but this was not observed. Sec-
ondly, the cross-sectional nature of this study does not
allow the antibody stability to be determined, and fur-
ther longitudinal studies will be required to address this.
Finally, exacerbations requiring hospitalisation was used
to determine frequent exacerbators. While this selects a
subset of severe exacerbations, we do not know whether
low anti-VP1 antibodies are associated with milder
exacerbations that resolve without requiring hospital
admission.
Conclusion
In conclusion, because rhinoviruses are so common, it is
easy to see how an impaired capacity to generate anti-
bodies directed to a protein that is cross-neutralising
across multiple rhinovirus strains could have an adverse
impact on the risk of COPD exacerbations. The mechan-
ism leading to such a specific deficit in humoral immunity
to rhinoviruses warrants further investigation.
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